当前位置: X-MOL 学术Lancet Diabetes Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Metabolic surgery: one size fits all? - Authors' reply.
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2020-02-11 , DOI: 10.1016/s2213-8587(20)30027-9
Jøran Hjelmesæth 1 , Farhat Fatima 2 , Kåre Inge Birkeland 3 , Marius Svanevik 4 , Dag Hofsø 5
Affiliation  

We thank Bengt Novik for his interest in our randomised controlled Oseberg trial and for the opportunity to respond and present our results stratified according to the Individualized Metabolic Surgery Score (IMSS). The IMSS classifies patients with diabetes according to their chances of partial remission of diabetes (HbA1c <6·5% off antidiabetes medication). The preoperative characteristics of Oseberg participants, including duration of diabetes and number of antidiabetes medications, did not differ substantially from the characteristics of patients retrospectively included in the study by Aminian and colleagues to construct and validate the IMSS ().

中文翻译:

代谢手术:一种尺寸适合所有人吗?-作者的答复。

我们感谢Bengt Novik对我们在Oseberg随机对照试验中的兴趣以及有机会根据我们的个体化​​代谢手术评分(IMSS)对我们的结果进行分层和分层。IMSS根据糖尿病患者部分缓解的机会对糖尿病患者进行分类(抗糖尿病药的HbA 1c <6·5%)。Oseberg参与者的术前特征(包括糖尿病持续时间和抗糖尿病药物的数量)与Aminian及其同事为构建和验证IMSS而在研究中回顾性纳入的患者特征没有实质性差异。
更新日期:2020-03-19
down
wechat
bug